secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001628280-25-052083
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio Q3 net loss $18.1M; cash $12.2M; ASH data ahead
---------------------------------------------------------

- Cash and cash equivalents $12.2M as of Sep 30, 2025, down from $48.3M at Dec 31, 2024.
- Net loss $18.1M ($0.69 per share) for Q3 2025; R&D expense $10.5M, G&A $6.4M.
- Phase 1 SENTI-202 in AML: updated clinical data to be presented at ASH meeting Dec 6-9, 2025.
- Abstracts accepted for oral and poster presentations at ASH; company will host webcast.
- No revenue; pre-commercial biotech focused on gene circuit platform for cell therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000162828025052083/0001628280-25-052083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000162828025052083/snti-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-052083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer